STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1129 by analyst upside · 2026-08-13
PRAX
Praxis Precision Medicines, Inc.
Healthcare · Market Cap $11B · P/E 0x
ANALYST PRICE TARGET
+61.4%
implied upside to consensus target
Current Price $386.33
Consensus Target $623.68
Bull Target $1201.0
Bear Target $188.0
Analysts Covering 19
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
14
Hold
1
Sell
1
52-Week Low $37.19
52-Week High $386.66
YTD Return +34.9%
FUNDAMENTALS
Market Cap $11B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-13.96
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $37.19
52-Week High $386.66
Current Price $386.33
Bear Target $188.0
Bull Target $1201.0
● Now $386.33 ● Target $623.68
TRADING DATA
Avg Volume 495K
YTD Return +34.9%
Analyst Count 19
Consensus Buy
Upside to Target +61.4%
Last Updated 2026-08-13

ANALYST SUMMARY

Praxis Precision Medicines, Inc. (PRAX) is currently trading at $386.33 with a Wall Street consensus price target of $623.68, implying potential upside of 61.4% over the next 12 months. 19 analysts currently cover PRAX, with a consensus rating of Buy - 89% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $1201.0, while the most cautious has a target of $188.0.

PRAX operates in the Healthcare sector with a market capitalisation of $11B. The stock is up 34.9% year-to-date and is currently trading near the upper end of its 52-week range of $37.19 – $386.66.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for PRAX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

RBC Capital ● Initiated
Outperform 2026-06-18 Building track record
Oppenheimer - Reiterated
Outperform → Outperform 2026-06-02 14% win rate (7 calls)
Truist Securities - Reiterated
Buy → Buy 2026-06-02 Building track record
Deutsche Bank - Reiterated
Buy → Buy 2026-06-02 Building track record
Wedbush - Reiterated
Underperform → Underperform 2026-06-02 Building track record
Baird - Reiterated
Outperform → Outperform 2026-06-02 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-06-02 31% win rate (48 calls)
BTIG - Reiterated
Buy → Buy 2026-06-02 38% win rate (8 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
45
out of 100
Coverage depth
23/30
Consensus clarity
0/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →